Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
暂无分享,去创建一个
A. Hemminki | A. Kanerva | J. Tapper | R. Havunen | J. Santos | V. Cervera-Carrascón | Dafne C A Quixabeira | T. Kudling | Susanna Grönberg-Vähä-Koskela | C. Heiniö | James H A Clubb | J. Clubb | S. Grönberg-Vähä-Koskela | D. Quixabeira
[1] A. Hemminki,et al. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1 , 2022, Oncoimmunology.
[2] M. Fuentes,et al. Autoimmune Responses in Oncology: Causes and Significance , 2021, International journal of molecular sciences.
[3] Wei Zhang,et al. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study , 2021, Frontiers in Immunology.
[4] C. Czerlanis,et al. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs , 2020, Cancers.
[5] A. Hemminki,et al. Oncolytic viruses for cancer immunotherapy , 2020, Journal of Hematology & Oncology.
[6] A. Hemminki,et al. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling , 2020, Cells.
[7] T. D. de Gruijl,et al. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity , 2020, Journal for ImmunoTherapy of Cancer.
[8] A. Hemminki,et al. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition , 2020, Oncoimmunology.
[9] L. Sánchez-Lorenzo,et al. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising? , 2019, Cancer.
[10] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. , 2019, European journal of cancer.
[11] J. Larkin,et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.
[12] T. Randall,et al. Overcoming immune suppression with epigenetic modification in ovarian cancer. , 2019, Translational research : the journal of laboratory and clinical medicine.
[13] S. Berceli,et al. Expression of a Functional IL-2 Receptor in Vascular Smooth Muscle Cells , 2018, The Journal of Immunology.
[14] A. Hemminki,et al. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus , 2018, Molecular therapy oncolytics.
[15] Y. Kodera,et al. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers , 2018, Cancers.
[16] E. Carapuça,et al. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses , 2018, Porto biomedical journal.
[17] N. Lemoine,et al. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer , 2018, Front. Immunol..
[18] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[19] K. Savage,et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Sequist,et al. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care , 2017, Cell reports.
[21] F. Lang,et al. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. , 2017, Cancer research.
[22] D. Nettelbeck,et al. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy , 2016, Molecular therapy oncolytics.
[23] J. Hawiger,et al. Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of Adherens Junctions* , 2016, The Journal of Biological Chemistry.
[24] M. Kiechle,et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer , 2016, British Journal of Cancer.
[25] A. Hemminki,et al. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] J. Mathis,et al. Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting , 2016, Oncoimmunology.
[27] A. Hemminki,et al. Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors , 2015, PloS one.
[28] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[29] A. Dudley,et al. A three-party alliance in solid tumors , 2013, Adipocyte.
[30] A. Goy,et al. Early Detection Biomarkers for Ovarian Cancer , 2012, Journal of oncology.
[31] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[32] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[33] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[34] B. Aggarwal,et al. TNF-Induced Signaling in Apoptosis , 1999, Journal of Clinical Immunology.
[35] A. Oberg,et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. , 2015, Cancer research.
[36] E. Aktas,et al. Relationship between CD107a expression and cytotoxic activity. , 2009, Cellular immunology.